Neurenati Appoints Dr. Meriam Kabbaj as Chief Development Officer and Secures $1.7M Seed Financing
Position
Chief Development Officer
Company
Neurenati Therapeutics
MontrealBiotechnologyHealth CareTherapeuticsDescription
Neurenati Therapeutics is pleased to announce the appointment of Dr. Meriam Kabbaj, DPharm, PhD, as Chief Development Officer. The company also successfully closed a $1.7M extended seed financing led by Genson Capital and Invest Quebec, providing sufficient capital for cGMP production of the neurotrophic growth factor, initiation of the IND-enabling preclinical studies for NEU-001, and team expansion.
Quick answer
Neurenati Appoints Dr. Meriam Kabbaj as Chief Development Officer and Secures $1.7M Seed Financing (March 4, 2025). Neurenati Therapeutics is based in Montreal, Quebec, Canada.
- Who is the new Chief Development Officer at Neurenati Therapeutics?
- Neurenati Therapeutics named Meriam Kabbaj Chief Development Officer, announced March 4, 2025.
- What did Neurenati Therapeutics announce on March 4, 2025?
- Neurenati Therapeutics is pleased to announce the appointment of Dr. Meriam Kabbaj, DPharm, PhD, as Chief Development Officer. The company also successfully closed a $1.7M extended seed financing led by Genson Capital and Invest Quebec, providing sufficient capital for cGMP production of the neurotrophic growth factor, initiation of the IND-enabling preclinical studies for NEU-001, and team expansion.
- What does Neurenati Therapeutics do?
- Neurenati Therapeutics is a Québec-based biotech company dedicated to developing therapies for rare diseases.
- Where is Neurenati Therapeutics based?
- Neurenati Therapeutics is based in Montreal, Quebec, Canada.
- Which similar companies made leadership changes around the same time?
- Imugene (March 4, 2025), Alcresta Therapeutics (March 3, 2025), SAGE Therapeutics (March 7, 2025) and FoRx Therapeutics (February 26, 2025) also announced leadership changes within 45 days of Neurenati Therapeutics.
Source: Fundz verified event record.
Other recent leadership changes in Therapeutics and Biotechnology
Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.
- Imugene Appoints Darren Keamy as Chief Financial Officer and Company Secretary (March 4, 2025)
- Alcresta Therapeutics, Inc. names Jason Weiner as Chief Strategy and Business Development Officer and Chris Arnold as Chief Commercial Officer (March 3, 2025)
- Sage Therapeutics appoints Michael Quirk, Ph.D. as Chief Medical Officer after Laura Gault steps down (March 7, 2025)
- FoRx Therapeutics Appoints Jens Würthner as Chief Medical Officer (February 26, 2025)
- Crinetics Pharmaceuticals Appoints Tobin “Toby” Schilke as Chief Financial Officer (February 26, 2025)
- Crescent Biopharma, Inc. Appoints Wenjie Cheng as Senior Vice President of Technical Operations, Ryan Lynch as Chief Accounting Officer, and Barbara Bispham as General Counsel (February 24, 2025)
Who to call at Neurenati Therapeutics, and when
A new leader at Neurenati Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.
- An alert the day Neurenati Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Neurenati Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Neurenati Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Neurenati Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Neurenati Therapeutics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.